TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlyingAATD, with Investigational New Drug filing expected by the end of the year  Tessera to receive $150 million, inclusive of a cash upfront and equity investment fromRegeneron; companies to share worldwide development costs and future profits 50:50 Collaboration combines Regeneron’s long-standing expertise in genetics, genetic medicines andclinical development with Tessera’s pioneering